Article Details

Drugmaker's DME candidate hits mark in two Phase III studies

Retrieved on: 2021-01-05 21:45:00

Tags for this article:

Click the tags to see associated articles and topics

Drugmaker's DME candidate hits mark in two Phase III studies. View article details on hiswai:

Excerpt

Roche's fericimab is the focus of Yosemite and Rhine studies, which investigators say show it has the potential to offer lasting vision improvements for ...

Article found on: www.ophthalmologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up